Back to Diseases List
Associated Genetic Biomarkers
Esophagogastric carcinomas most frequently harbor alterations in TP53, CDKN2A, ERBB2, ARID1A, and KRAS .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 8 Mutation, and TP53 Exon 5 Mutation are the most common alterations in esophagogastric carcinoma .
There are 18 clinical trials for esophagogastric carcinoma, of which 15 are open and 3 are completed or closed. Of the trials that contain esophagogastric carcinoma as an inclusion criterion, 9 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), and 5 are phase 2 (4 open).
Deficient, HER2, and MLH1 are the most frequent gene inclusion criteria for esophagogastric carcinoma clinical trials .
Pembrolizumab, etrumadenant, and fluorouracil are the most common interventions in esophagogastric carcinoma clinical trials.
Significant Genes in Esophagogastric Carcinoma
NTRK1 is altered in 2.32% of esophagogastric carcinoma patients .
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for esophagogastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and esophagogastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.